AURA Insider Trading (Aura Biosciences)
Insider Ownership Percentage: 5.00%
Insider Buying (Last 12 Months): $430,200.00
Insider Selling (Last 12 Months): $0.00
Aura Biosciences Share Price & Price History
Current Price: $18.99
Price Change: ▲ Price Increase of +1.55 (8.89%)
As of 08/12/2022 01:00 AM ET
A One Stop Shop for Everything Futures Trading
From RJO Futures | Ad
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.
Aura Biosciences Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
6/13/2022 | David Michael Johnson | Director | Buy | 20,000 | $13.99 | $279,800.00 | 30,000 | |
6/10/2022 | David Michael Johnson | Director | Buy | 10,000 | $15.04 | $150,400.00 | 10,000 | |
A One Stop Shop for Everything Futures Trading
From RJO Futures | Ad
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.
Aura Biosciences Institutional Trading History
Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
---|
8/13/2022 | American International Group Inc. | 8,577 | $0.12M | 0.0% | +208.3% | 0.029% |  |
8/12/2022 | Northern Trust Corp | 132,692 | $1.88M | 0.0% | +188.0% | 0.453% |  |
8/12/2022 | FMR LLC | 603,471 | $8.55M | 0.0% | +22.1% | 2.062% |  |
8/12/2022 | Rhumbline Advisers | 20,713 | $0.29M | 0.0% | N/A | 0.071% |  |
8/11/2022 | UBS Group AG | 16,320 | $0.23M | 0.0% | +2,064.5% | 0.056% |  |
8/11/2022 | JPMorgan Chase & Co. | 9,798 | $0.14M | 0.0% | +272.8% | 0.033% |  |
8/3/2022 | Regency Capital Management Inc. DE | 254,622 | $3.61M | 3.9% | N/A | 0.870% |  |
6/7/2022 | Bank of America Corp DE | 11,857 | $0.26M | 0.0% | +53.5% | 0.041% |  |
5/16/2022 | California State Teachers Retirement System | 2,358 | $52K | 0.0% | -21.8% | 0.008% |  |
5/16/2022 | State Street Corp | 84,982 | $1.87M | 0.0% | +80.1% | 0.291% |  |
5/13/2022 | Charles Schwab Investment Management Inc. | 15,379 | $0.34M | 0.0% | +30.1% | 0.053% |  |
5/13/2022 | Nantahala Capital Management LLC | 301,990 | $6.64M | 0.3% | +204.6% | 1.034% |  |
5/13/2022 | Vanguard Group Inc. | 228,633 | $5.03M | 0.0% | +1.0% | 0.782% |  |
5/12/2022 | BlackRock Inc. | 275,027 | $6.05M | 0.0% | +15.2% | 0.941% |  |
5/11/2022 | Bank of New York Mellon Corp | 14,496 | $0.32M | 0.0% | N/A | 0.050% |  |
5/11/2022 | JPMorgan Chase & Co. | 2,628 | $58K | 0.0% | -60.2% | 0.009% |  |
5/10/2022 | Decheng Capital Management III Cayman LLC | 210,000 | $4.62M | 1.4% | N/A | 0.719% |  |
5/5/2022 | New York State Common Retirement Fund | 6,252 | $0.14M | 0.0% | +134.3% | 0.021% |  |
2/16/2022 | Matrix Capital Management Company LP | 4,112,870 | $69.84M | 0.8% | N/A | 14.080% |  |
2/15/2022 | Adage Capital Partners GP L.L.C. | 1,255,480 | $21.32M | 0.0% | N/A | 4.298% |  |
2/14/2022 | Citadel Advisors LLC | 2,315,102 | $37.32M | 0.0% | N/A | 7.925% |  |
2/11/2022 | Allianz Asset Management GmbH | 55,145 | $0.94M | 0.0% | N/A | 0.189% |  |
2/8/2022 | Northern Trust Corp | 45,875 | $0.78M | 0.0% | N/A | 0.157% |  |
2/3/2022 | Medicxi Ventures Management Jersey Ltd | 3,039,892 | $51.62M | 12.9% | N/A | 10.407% |  |
2/2/2022 | New York State Common Retirement Fund | 2,668 | $45K | 0.0% | N/A | 0.009% |  |
Data available starting January 2016
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Read More on Aura Biosciences
Today's Range
Now: $18.99
52 Week Range
Now: $18.99
Volume
52,625 shs
Average Volume
43,539 shs
Market Capitalization
$555.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Aura Biosciences?
Who are the major institutional investors of Aura Biosciences?
Which institutional investors are buying Aura Biosciences stock?
Within the previous quarter, AURA stock was bought by institutional investors including:
- Regency Capital Management Inc. DE
- FMR LLC
- Northern Trust Corp
- Rhumbline Advisers
- UBS Group AG
- JPMorgan Chase & Co.
- American International Group Inc.